Lv4
480 积分 2021-10-24 加入
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
7小时前
已完结
Effect of Food on the Pharmacokinetic Characteristics of a Single Oral Dose of D-1553, a Selective Inhibitor of KRASG12C, in Healthy Chinese Subjects
21天前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
21天前
已完结
Pharmacokinetics, mass balance, and metabolism of [14C]envonalkib (TQ-B3139), a novel ALK tyrosine kinase inhibitor, in healthy Chinese subjects
21天前
已完结
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
1个月前
已完结
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
1个月前
已完结
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
1个月前
已完结
Management of HER2 alterations in non-small cell lung cancer - The past, present, and future
1个月前
已完结
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer
1个月前
已完结
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer
1个月前
已完结
皖公网安备34019202002308
